TrakCel Strengthens Board with Addition of Peter Wright
TrakCel, a provider of supply chain management technology for cell therapies, today announced former strategic investment director of Finance Wales, Peter Wright, will join the firm as a non-executive board member. He will help guide the firm through its commercial growth phase as TrakCel strives to acquire further cell therapy development clients in 2015.
Mr Wright was a strategic investment director at Finance Wales plc from 2013 until October 31, 2014, having joined as an investment director in November 2004. Previously, he held senior positions at Fortis Bank, Natwest Bank and RBS.
He joins the board as TrakCel commences its growth strategy, having completed a recent round of investment funding. Since the beginning of 2015 TrakCel has completed a series of new appointments, expanded marketing activities and acquired larger office facilities to support the growth plan.
“I believe TrakCel’s innovative technology will accelerate the development of cell therapies and will have a profound impact on the advancement of healthcare.” said Peter Wright. ”I’m excited to join at a time when the company is aspiring to present itself on the global stage.”
In 2014, TrakCel established a foothold in the biotechnology marketplace by announcing partnerships with GlaxoSmithKline and The Cell Therapy Catapult. The company is focused on growing globally in 2015, having completed a series of exhibitions and presentations and early client engagements in the first quarter.
“Peter Wright has a wealth of experience in working with small and medium sized companies in their growth phase” said Keren Winmill, Chairperson, TrakCel, “We’ll be in a much stronger position as a board to steer the company as we cope with the pressures of expansion.”
TrakCel will be expanding its team to support growth initiatives including roles in business development, customer support, software development and technical operations.